INNOVENT BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.75 HKD | +1.53% |
|
+19.73% | -7.02% |
| 04-17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
| 04-02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
ETFs positioned on Innovent Biologics, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.78% | 2 M€ | -14.86% | - | |
| 1.77% | 4 M€ | -27.92% | ||
| 1.09% | 1 M€ | -9.86% | - | |
| 0.68% | 2 M€ | -14.14% | ||
| 0.08% | 35 M€ | -5.85% | - | |
| 0.07% | 2,808 M€ | +6.68% | - | |
| 0.07% | 441 M€ | +4.60% | - | |
| 0.07% | 149 M€ | +2.17% | - | |
| 0.07% | 4 M€ | -4.41% | - | |
| 0.06% | 117 M€ | +1.66% | - | |
| 0.02% | 31 M€ | +3.97% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 389 M€ | +6.76% | - | |
| 0.01% | 34 M€ | +2.67% | - | |
| 0.01% | 7 M€ | +1.95% | - | |
| 0.01% | 108 M€ | +2.34% | - | |
| 0.01% | 17 M€ | +1.44% | - | |
| 0.01% | 34 M€ | +6.71% | - | |
| 0.00% | 52 M€ | -0.13% | - | |
| 0.00% | 8 M€ | -0.60% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 302 M€ | +4.32% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 15 M€ | +11.24% |
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkinâs lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
36.24
CNY
Average target price
51.18
CNY
Spread / Average Target
+41.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.02% | 8.12B | |
| -4.06% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -13.70% | 15.36B | |
| -8.82% | 11.95B | |
| -15.64% | 11.6B | |
| -41.58% | 11.51B | |
| +6.14% | 8.71B | |
| +2.51% | 7.72B |
- Stock Market
- Equities
- 1801 Stock
- Funds and ETFs Innovent Biologics, Inc.
